BOSTON – Aileron Therapeutics, a clinical-stage firm in the field of stapled peptide therapeutics for cancers and other diseases, will relocate from Cambridge to 18,609 square feet of space, while Kala Pharmaceuticals, Inc. (NASDAQ: KALA), a biopharmaceutical company focused on the development and commercialization of innovative treatments for ocular diseases, will relocate to 66,053 square feet of space within the LINX building at 490 Arsenal Way in Watertown, announced Cushman & Wakefield and the building owner, Boylston Properties.
“With the addition of Aileron Therapeutics, LINX is officially at 100% capacity, and it shows the appeal of the East End of Watertown is alive and well,” said Bill McQuillan, President of Boylston Properties.
“Aileron Therapeutics’ relocation from Cambridge further highlights how desirable the East End of Watertown has become to life sciences companies,” said Duncan Gratton, Executive Director at Cushman & Wakefield. “Watertown continues to be an attractive location for companies seeking a more affordable alternative to Kendall Square that’s still in close proximity to Cambridge and Boston.”
Gratton and Kate Lien, Senior Director at Cushman & Wakefield, represented Boylston Properties in the transaction.
Aileron Therapeutics was represented by Dave Townsend, Executive Managing Director at Newmark Knight Frank.Kala Pharmaceuticals was represented by Sam Crossan, Vice President and Rob Walles, Senior Vice President/Partner of CBRE.
Located at 490 Arsenal Way, LINX is a 185,000-square-foot creative office and lab building in the East End of Watertown, a neighborhood undergoing a tremendous renaissance. The two-story building opened in the summer of 2017 and includes numerous amenities highlighted by an acre of outdoor green and recreation space, a 33-foot high lobby area with a café, bike storage for 78 bicycles and a high-end shower and locker facility. LINX also offers abundant free parking and a private shuttle bus to Harvard Square and the MBTA Red Line.